Do regulatory antibodies offer an alternative mechanism to explain the hygiene hypothesis?

Trends in Parasitology

Volumn 27, Issue 12, 2011, Pages 523-529

  Mekhaiel, David N A ^a   Daniel Ribeiro, Claudio T ^b   Cooper, Philip J ^a   Pleass, Richard J ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G;

ANTIGEN ANTIBODY COMPLEX; ENVIRONMENTAL SANITATION; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNE RESPONSE; INFECTION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; REVIEW;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES; ANTIGEN-ANTIBODY COMPLEX; AUTOIMMUNE DISEASES; CHILD; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HUMANS; HYGIENE HYPOTHESIS; HYPERGAMMAGLOBULINEMIA; HYPERSENSITIVITY; MODELS, IMMUNOLOGICAL; PARASITES; PARASITIC DISEASES; T-LYMPHOCYTES, REGULATORY;

VERMES;

EID: 82855165065     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2011.08.003     Document Type: Review

References (88)

1. Cooper P.J. Interactions between helminth parasites and allergy. Curr. Opin. Allergy Clin. Immunol. 2009, 9:29-37.
2. Smith M.A., et al. Evidence that childhood acute lymphoblastic leukemia is associated with an infectious agent linked to hygiene conditions. Cancer Causes Control 1998, 9:285-298.
3. Harnett W., Harnett M.M. Helminth-derived immunomodulators: can understanding the worm produce the pill?. Nat. Rev. Immunol. 2010, 10:278-284.
4. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J. Allergy Clin. Immunol. 2011, 127:315-323.
5. Orange J.S., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 2006, 117:S525-S553.
6. Jann S., et al. Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow up. J. Neurol. Neurosurg. Psychiatry 2009, 80:70-73.
7. Inoue Y., et al. Activating Fcγ receptors participate in the development of autoimmune diabetes in NOD mice. J. Immunol. 2007, 179:764-774.
8. Debré M., et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993, 342:945-949.
9. Samuelsson A., et al. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
10. Bazin R., et al. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br. J. Haematol. 2006, 135:97-100.
11. Crow A.R., et al. IVIg-mediated amelioration of murine ITP via FcγRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 2003, 102:558-560.
12. Araujo L.M., et al. Intravenous Ig inhibits invariant NKT cell-mediated allergic airway inflammation through FcγRIIIA-dependent mechanisms. J. Immunol. 2011, 186:3289-3293.
13. Teeling J.L., et al. Therapeutic efficacy of IVIG preparations depends on IgG dimers: studies in experimental immune thrombocytopenia. Blood 2001, 98:1095-1099.
14. Machino Y., et al. Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP). Clin. Exp. Immunol. 2010, 162:415-424.
15. Anthony R.M., et al. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:19571-19578.
16. Séïté J.F., et al. IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature B lymphocytes. Blood 2010, 116:1698-1704.
17. Anthony R.M., et al. Intravenous gammaglobulin suppresses inflammation through a novel Th2 pathway. Nature 2011, 475:110-113.
18. Min B., et al. Basophils produce IL-4 and accumulate in tissues after infection with a Th2-inducing parasite. J. Exp. Med. 2004, 200:507-517.
19. Liew F.Y., et al. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 2010, 10:103-110.
20. Melendez A.J., et al. Inhibition of Fc epsilon RI-mediated mast cell responses by ES-62, a product of parasitic filarial nematodes. Nat. Med. 2007, 13:1375-1381.
21. Meyer S., et al. DC-SIGN mediates binding of dendritic cells to authentic pseudo-Lewis Y glycolipids of Schistosoma mansoni cercariae, the first parasite-specific ligand of DC-SIGN. J. Biol. Chem. 2005, 280:37349-37359.
22. Roux K.H., Tankersley D.L. A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J. Immunol 1990, 144:1387-1395.
23. Yoo E.M., et al. Human IgG2 can form covalent dimers. J. Immunol. 2003, 170:3134-3138.
24. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 2008, 26:513-533.
25. Rowe D.S., et al. Plasma immunoglobulin concentrations in a West African (Gambian) community and in a group of healthy British adults. Clin. Exp. Immunol. 1968, 3:63-79.
26. Mibei E.K., et al. Immune complex levels in children with severe Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 2005, 72:593-599.
27. Virgin H.W., Unanue E.R. Suppression of the immune response to Listeria monocytogenes. Immune complex inhibit resistance. J. Immunol. 1984, 133:104-109.
28. Goes A.M., et al. Granulomatous hypersensitivity to Schistosoma mansoni egg antigens in human schistosomiasis. III. In vitro granuloma modulation induced by immune complexes. Am. J. Trop. Med. Hyg. 1991, 44:434-443.
29. Lawley T.J., et al. Circulating immune-complexes in acute schistosomiasis. Clin. Exp. Immunol. 1979, 37:221-227.
30. Ferrari T.C.A., et al. Identification and characterization of immune complexes in the cerebrospinal fluid of patients with spinal cord schistosomiasis. J. Neuroimmunol. 2011, 230:188-190.
31. Regnault A., et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 1999, 189:371-380.
32. Schuurhuis D.H., et al. Immune complex-loaded dendritic cells are superior to soluble immune-complexes as antitumor vaccine. J. Immunol. 2006, 176:4573-4580.
33. Heyman B. Regulation of antibody responses via antibodies, complement, and Fc-receptors. Annu. Rev. Immunol. 2000, 18:709-737.
34. Zhang Y., et al. Immune-complex/Ig negatively regulates TLR4-triggered inflammatory response in macrophages through FcγRIIb-dependent PGE2 production. J. Immunol. 2009, 182:554-562.
35. Zhang Y., et al. Immune complex enhances tolerogenicity of immature dendritic cells via FcγRIIb and promotes FcγRIIb-overexpressing dendritic cells to attenuate lupus. Eur. J. Immunol. 2011, 41:1-11.
36. Pleass R.J. When is a malaria immune complex not an immune complex?. Parasit. Immunol. 2009, 31:61-63.
37. Harte P.G., et al. Failure of malaria vaccination in mice born to immune mothers. Clin. Exp. Immunol. 1982, 49:509-516.
38. Gans H.A., et al. Deficiency of the humoral response to measles vaccine in infants immunized at age 6 months. J. Am. Med. Assoc. 1998, 280:527-532.
39. Perkins F.T., et al. Responses of 6- and 9-months old infants to two and three doses of poliomyelitis vaccine. Br. Med. J. 1959, 1:530-532.
40. Kim D., et al. Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies. Blood 2011, 117:6143-6151.
41. Harte P.G., et al. Specific monoclonal IgM is a potent adjuvant in murine malaria vaccination. Nature 1983, 302:256-258.
42. Cohen S. Host-parasite interface: evasion. Tropical and Geographical Medicine 1985, 138-146. McGraw-Hill Book Company. K.S. Warren, A.A.F. Mahmoud (Eds.).
43. Phillips T.M. Immune complex assays: diagnostic and clinical application. Crit. Rev. Clin. Lab. Sci. 1989, 27:237-264.
44. Greenwood B.M. Possible role for a B cell mitogen in hypergammaglobulinemia in malaria and trypanosomiasis. Lancet 1974, 303:435-436.
45. Devalapalli A.P., et al. Increased levels of IgE and autoreactive, polyreactive IgG in wild rodents: implications for the hygiene hypothesis. Scand. J. Immunol. 2006, 64:125-136.
46. Smith K.G., Clatworthy M.R. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 2010, 10:328-343.
47. Daniel-Ribeiro C.T., Zanini G. Autoimmunity and malaria: what are they doing together?. Acta Trop. 2000, 76:205-221.
48. Rahman M.A.A., Isenberg D.A. Glycosylation of IgG in rheumatic disease. Abnormalities of IgG Glycosylation and Immunological Disorders 1996, 101-118. John Wiley & Sons. D.A. Isenberg, T.W. Rademacher (Eds.).
49. Pilkington C., et al. Agalactosyl IgG and antibody specificity in rheumatoid arthritis, tuberculosis, systemic lupus erythematosus and myasthenia gravis. Autoimmunity 1995, 22:107-111.
50. Roy E., et al. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect. Immun. 2005, 73:6101-6109.
51. Wang J., et al. Fc-glycosylation of IgG1 is modulated by B cell stimuli. Mol. Cell. Proteomics 2011, 10. M110.004655. Epub 2011 Mar 3.
52. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 2009, 8:226-234.
53. Allhorn M., Collin M. Sugar-free antibodies - the bacterial solution to autoimmunity?. Ann. N. Y. Acad. Sci. 2009, 1173:664-669.
54. Albert H.M., et al. In vivo modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:15005-15009.
55. Adjobimey T., Hoerauf A. Induction of immunoglobulin G4 in human filariasis: an indicator of immuneregulation. Ann. Trop. Med. Parasitol. 2010, 104:455-464.
56. King I.L., et al. A nonredundant role for IL-21 receptor signaling in plasma cell differentiation and protective type 2 immunity against gastrointestinal helminth infection. J. Immunol. 2010, 185:6138-6145.
57. Ramakrishna C., et al. Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathog. 2011, 7:e1002071.
58. Reina Ortiz M., et al. Effects of chronic ascariasis and trichuriasis on cytokine production and gene expression in human blood: a cross-sectional study. PLoS Negl. Trop. Dis. 2011, 5:e1157.
59. Walsh K.P., et al. Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses. J. Immunol. 2009, 183:1577-1586.
60. Maddur M.S., et al. Inhibition of differentiation, amplification, and function of human Th17 cells by intravenous immunoglobulin. J. Allergy Clin. Immunol. 2011, 127:823-830.
61. Smith K.A., et al. Chronic helminth infection promotes immune regulation in vivo through dominance of CD11cloCD103-dendritic cells. J. Immunol. 2011, 186:7098-7109.
62. Strait R.T., et al. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and FcγRIIb cross-linking. J. Clin. Invest. 2006, 116:833-841.
63. Butterworth A.E., et al. Human immunity to Schistosoma mansoni: observations on mechanisms, and implications for control. Immunol. Invest. 1992, 21:391-407.
64. Hussain R., et al. Control of allergic reactivity in human filariasis. Predominant localization of blocking antibody to the IgG4 subclass. J. Immunol. 1992, 148:2731-2737.
65. Ephrem A., et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008, 111:715-722.
66. Kessel A., et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J. Immunol. 2007, 179:5571-5575.
67. De Groot A.S., et al. Activation of natural regulatory T cells by IgG Fc-derived peptide " Tregitopes" Blood 2008, 112:3303-3311.
68. Mosconi E., et al. Breast milk immune-complexes are potent inducers of oral tolerance in neonates and prevent asthma development. Mucosal Immunol. 2010, 3:461-474.
69. Wammes L.J., et al. Regulatory T cells in human geohelminth infection suppress immune responses to BCG and Plasmodium falciparum. Eur. J. Immunol. 2010, 40:437-442.
70. Roopenian D.C., Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 2007, 7:15-25.
71. Park-Min K.H., et al. FcγRIII-dependent inhibition of interferon-γ responses mediates suppressive effects of intravenous immune globulin. Immunity 2007, 26:67-78.
72. Clynes R. Protective mechanisms of IVIG. Curr. Opin. Immunol. 2007, 19:646-651.
73. Thomas B.N., Buxbaum L.U. FcγRIII mediates IgG induced IL-10 and is required for chronic Leishmania mexicana lesions. Infect. Immun. 2008, 76:623-631.
74. Anthony R.M., Ravetch J.V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Invest. 2010, 30:S9-S14.
75. Kaneko Y., et al. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313:670-673.
76. Lazarus A.H., et al. Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action. Transfus. Sci. 1998, 19:289-294.
77. Phillips S.M., et al. The regulation of resistance to Schistosoma mansoni by auto-anti-idiotypic immunity. J. Immunol. 1988, 141:1728-1733.
78. Contini C., et al. Evidence of cerebrospinal fluid free kappa light chains in AIDS patients with Toxoplasma gondii encephalitis. J. Neuroimmunol. 2000, 108:221-226.
79. Meixlsperger S., et al. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity 2007, 26:323-333.
80. Van der Neut Kolfschoten M., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
81. Rispens T., et al. Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions. J. Immunol. 2009, 182:4275-4281.
82. Ehrenstein M.R., et al. Deficiency in serum immunoglobulin M (IgM) predisposes to development of IgG autoantibodies. J. Exp. Med. 2000, 191:1253-1258.
83. Ehrenstein M.R., Notley C.A. the importance of natural IgM: scavenger, protector and regulator. Nat. Rev. Immunol. 2010, 10:778-786.
84. Senaldi G., et al. IgM reduction in systemic lupus erythematosus. Arthritis Rheum. 1988, 31:1213.
85. Hurez V., et al. Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 1997, 90:4004-4013.
86. Vassilev T., et al. IgM-enriched human IVIG suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice. Clin. Exp. Immunol. 2006, 145:108-115.
87. Monteiro R.C. The role of IgA and IgA Fc receptors as anti-inflammatory agents. J. Clin. Immunol. 2010, 30:S61-S64.
88. Russell M.W., Kilian M. Biological activities of IgA. Mucosal Immunology 2005, Vol. 1:267-289. Elsevier Academic Press.